

Original Research Article

GLYCAEMIC CONTROL AND EVIDENCES OF ISCHAEMIC HEART DISEASE OF KNOWN TYPE 2 DIABETICS ATTENDING THE ENDOCRINOLOGY CLINIC AT THE FEDERAL MEDICAL CENTRE, YENAGOA

ABSTRACT

Introduction: Diabetes mellitus is a chronic disease with life-threatening complications with cardiovascular complications being the major cause of death among those with type 2 diabetes.

Aim: The study was aimed at evaluating the glycemic status and evidences of Ischaemic heart disease, associated with type 2 diabetes mellitus among diabetic patients attending the endocrinology clinic in FMC Yenagoa during the study period.

Materials and Methods: The study made use of 162 apparently healthy individuals and 300 diabetic patients. Interviewer-administered questionnaire and fasting blood sugar were the study tools. The data obtained were analyzed using descriptive statistics and paired sample T-test.

Results and Discussion: The results revealed that the body mass index (BMI), blood pressure (BP) and fasting blood sugar (FBS) of the diabetics were significantly higher than those of the non-diabetics. Again, 41.7% of the experimental subjects had a normal glycemic control, 49.7% had a fair glycemic control while 8.7% of them had a poor glycemic control. The symptoms of Ischaemic heart disease associated with type 2 diabetes in the experimental subjects were chest pain, chest discomfort, pain in the leg, ischaemic gangrene and loss of strength. Again, age, gender, BMI, smoking and FSB were other risk factors found to be associated with ischaemic heart disease.

Conclusion and Recommendation: Implementing lifestyle changes such as regular exercise, a healthy diet, and smoking cessation to reduce the risk of cardiovascular abnormalities in diabetics is recommended. A close and regular monitoring of the FBS, BP and cardiac abnormalities is also recommended for diabetic patients.

Keywords: *Diabetes mellitus, blood sugar, glycemic control, heart disease and symptoms*

INTRODUCTION

Diabetes mellitus (DM) refers to a set of metabolic diseases characterized by a rise in blood sugar (hyperglycemia) and abnormalities in insulin secretion, insulin activity, or both. ^[1] The pancreas can no longer generate insulin or when the body cannot effectively use the insulin it does produce, diabetes develops. ^[2] On a backdrop of insulin resistance, type 2 diabetes mellitus (T2DM) is brought on by a progressive loss of B-cell insulin production. ^[1] It is a chronic disease with life-threatening micro- and macro-vascular complications. ^[3] Multiple organ systems are affected by the disease, which is largely defined by hyperglycemia brought on by insufficient insulin secretion, ineffective insulin action, or occasionally a mix of both. It can

lead to early atherosclerosis, which can damage both the micro- and macro-vasculature and frequently manifest as nephropathy and coronary artery disease.^[4]

The American Diabetes Association (ADA) classifies DM into three broad categories: type 1 (insulin-dependent DM), type 2 (non-insulin-dependent DM), and gestational DM. DM is a significant and quickly rising public health issue in low- and middle-income countries. Globally, 387 million individuals have diabetes as of 2014, and by 2035, that figure is projected to grow by an additional 205 million. 77% of diabetics live in low- and middle-income countries, and nearly 46% of them have undiagnosed diabetes.^[5] The number of diabetic patients worldwide has increased from 108 million in 1980 to 465 million in 2019. Current forecasts indicate that by 2045, this number will surpass 700 million.^[6]

Diabetes is currently a worldwide epidemic. It is a formidable metabolic condition due to its evolution, which is typically subtle. This causes a delay in diagnosis, which in turn exposes patients to consequences, particularly cardiovascular.^[7]

The prevalence of diabetes mellitus is rising quickly worldwide, especially in middle- and low-income nations like Sub-Saharan, which is made worse by changes in socioeconomic conditions, dietary habits, and lifestyles.^[1]

The global prevalence of diabetes increased from 151 million in 2000 to 366 million in 2011 and is anticipated to reach 551 million by 2025.^[8] T2DM is currently on the rise throughout the world, with 80% of cases occurring in low- to middle-income nations.^[1] Changes in the human environment, behavior, and way of life have led to a major increase in the incidence and prevalence of diabetes among individuals with a genetic vulnerability to the disease.^[8] T2DM makes up 90–95% of all diabetes cases in Africa. Nearly 49.7% of diabetes cases worldwide and 69.2% of cases in Africa go untreated. T2DM may manifest with or without symptoms and

may result in long-term cardiovascular system harm.^[1] Numerous long-term consequences are connected with diabetes, including retinopathy, nephropathy, and neuropathy. Additionally, they are at risk for macrovascular problems, coronary artery disease (CAD), stroke, and peripheral vascular disease. More than 70% of type 2 diabetes patients die from cardiovascular disease.^[8]

AIM OF THE STUDY

This study was therefore carried out to evaluate the glycemic control and evidences of Ischaemic heart disease of known type 2 diabetic patients attending the endocrinology clinic at the Federal Medical Centre, Yenagoa.

MATERIALS AND METHODS

The glycaemic control and evidences of ischaemic heart disease was carried out at the endocrinology clinic of the federal medical centre in Yenagoa were described using a cross-sectional comparative study design. The Federal Medical Centre Yenagoa, often known as FMC Yenagoa, is a tertiary hospital located in Bayelsa State, Nigeria, in the heart of Yenagoa. It acts as a referral centre for patients from private and public hospitals in Bayelsa State and surrounding Rivers State villages.

Study population

The study population consisted of individuals with type 2 diabetes who attended the endocrinology clinic during the study period

Inclusion Criteria

- (1) Type 2 DM patients aged 35 and above, who fulfilled the following criteria for the diagnosis of diabetes mellitus
- (2) Symptoms of diabetes plus random blood glucose concentration ≥ 11.1 mmol/L (200 mg/dL) or Fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL) or Haemoglobin A1c $\geq 6.5\%$

(3) Patients with no cardiovascular complaints.

Exclusion criteria

(1) T2DM patients with concomitant diseases or conditions affecting lipid levels like chronic liver disease and hypothyroidism.

(2) Patients on drugs like oral contraceptive pills, steroids, diuretics, antiarrhythmics and anti-Ischaemic drugs.

(3) Patients with Type 1 DM

Study Tools

The study tools were an interviewer-administered questionnaire, a glucometer and ECG Leads.

Sample size determination

The sample size of this research was calculated using Taro Yamane (Yamane, 1973) formula which gave a 95% confidence level.

The calculation formula of Taro Yamane is presented as follows

$$n = \frac{N}{1 + N(e)^2}$$

Where:

n= sample size required

N=number of people in the population

e= allowable error (%) as 0.05

Substituting numbers on formula:

$$n = \frac{900}{1 + 900 \times 0.05 \times 0.05}$$

$$= \frac{900}{1 + 900 \times 0.0025}$$

$$= \frac{900}{1 + 2.25}$$

$$= \frac{900}{3.25} = 276.923 \text{ (calculated sample size)}$$

To ensure fairly reliable research data, the sample size for the study is therefore approximated to 280 participants.

Sampling Techniques

All consecutive diabetics who presented to the clinic and met the inclusion criteria were enrolled with their informed consent until the sample size requirement was met.

Data collection

The investigator administered a questionnaire to each participant. The investigator and trained research assistants explained the questionnaire in their local language to those who did not understand English but did comprehend Ijaw, Epie, or other Nigerian languages. The subject's demographic details were recorded, and a physical examination was performed. The body weight of each subject was determined with the person standing barefoot and on a Hanson bathroom scale (model 1989) with a 500g resolution. Each subject had his or her height measured in meters by standing barefoot on a flat platform with both heels against a wall in front of a wall meter rule. The formula for calculating the body mass index (BMI) was $BMI = \text{weight in kilograms divided by height squared in meters (kg/m}^2\text{)}$. Random blood sugar samples were also taken from participants. Physical examination was carried out to ascertain the cardiovascular status of the respondents.

Data Analysis

The random blood sugar measurements data were analysed statistically with the Statistical Package for the Social Sciences (SPSS 20.0). The mean values, frequencies, and standard deviation of continuous variables like age and weight were also calculated.

Ethical considerations

The University of Port Harcourt's Research and Ethics Committee provided ethical approval. Before delivering the questionnaire. Written informed consent was also obtained from participants.

RESULTS AND DISCUSSION

TABLE 1: SOCIO-DEMOGRAPHIC VARIABLES OF THE EXPERIMENTAL (DIABETIC) INDIVIDUALS.

Sociodemographic variables	Experimental group		
		Frequency	Percentage
Gender	Male	128	42.7
	Female	172	57.3
	Total	300	100
Age	30-39yrs	4	1.2
	40-49yrs	75	25.1
	50-59yrs	97	32.3
	60-69yrs	85	28.4
	70-79yrs	28	9.5
	80-89yrs	11	3.6
	Total	300	100
Educational Status of respondents	No formal education	50	16.7
	Primary	52	17.3
	Secondary	62	20.7
	Tertiary	136	45.3

	Total	300	100
Occupation	Unemployed	36	12.0
	Housewife	29	9.7
	Farming	50	16.7
	Fishing	29	9.7
	Teacher	20	6.7
	Trader	40	13.3
	Others	96	32.0
	Total	300	100
Religion	Christian	259	86.3
	Muslim	8	2.7
	Traditional worshipper	8	2.7
	Others	25	8.3
	Total	300	100

TABLE 2: SYMPTOMS OF ISCHAEMIC HEART DISEASE ASSOCIATED WITH TYPE 2 DIABETES IN THE EXPERIMENTAL SUBJECTS.

Age range	Chest pain	Chest discomfort	Pain anywhere else	Pain in the leg	Ischaemic gangrene	Weakness or loss of strength
30-39yrs	2	6	0	8	2	0
40-49yrs	17	10	4	11	5	2

50-59yrs	33	29	3	4	15	3
60-69yrs	34	30	6	2	18	3
70-79	10	8	7	12	5	6
80-89	6	3	8	9	9	8
Total	102	86	28	46	54	22
Gender						
Male	34	28	13	29	21	16
Female	68	58	15	27	33	6
Total	102	86	28	46	54	22

TABLE 3: GLYCEMIC AND OTHER RISK FACTORS ASSOCIATED WITH THE EXPERIMENTAL (DIABETIC) INDIVIDUALS

RISK FACTORS		Frequency	Percentage
Age	30-39yrs	4	1.2
	40-49yrs	75	25.1
	50-59yrs	97	32.3
	60-69yrs	85	28.4
	70-79yrs	28	9.5
	80-89yrs	11	3.6
	Total	300	100
Gender	Male	128	42.7
	Female	172	57.3
	Total	300	100

BMI	Underweight (<18.5)	0	0
	Normal weight (18.5-24.9)	76	25.3
	Overweight (25.0-29.9)	138	46.0
	Obesity class 1(30.0-34.9)	79	26.3
	Obesity class 2 (35.0-39.9)	5	1.7
	Extreme obesity (>40)	2	0.7
	Total	300	100
Smoking	Smokers	40	13.3
	Non-smokers	260	86.7
	Total	300	100
FBS	Good glycemic control (<6 mmol/l)	125	41.7
	Fair glycemic control (6-10mmol/l)	149	49.7
	Poor glycemic control (>10mmol/l)	26	8.7
	Total	300	100
Duration of diabetes	1-3 years	100	33.3
	4-6 years	110	36.7
	> 6 years	90	30.0
	Total	300	100

TABLE 4: PAIRED SAMPLE T-TEST RESULT SHOWING THE RELATIONSHIP BETWEEN SOME PARAMETERS OF THE CONTROL AND EXPERIMENTAL GROUPS

Variables	Control	Experimental	P-value
Age	57.40±0.82	60.58±0.82 ^a	0.01
BMI	27.34±0.19	29.96±0.28 ^a	0.00
Rate	76.97±0.84	77.42±0.87	0.70
Systolic blood pressure	123.33±1.01	127.83±1.30 ^a	0.01
Diastolic blood pressure	77.93±0.60	81.05±0.71 ^a	0.001
Fasting blood sugar	1.65±0.01	5.58±0.15 ^a	0.00

The data are presented as mean ± SEM with “a” representing a significant increase in the experimental group with respect to the control groups at p<0.05

DISCUSSION OF FINDINGS

Socio-demographic variables of the experimental (diabetic) individuals.

The socio-demographic variables of the diabetic patients are presented in table 1. The age range of the participants is from 30-89 years. Most of the participants (32.3%) are found within the age range of 60-69 years while the least population (1.2%) are between 30 years to 39 years. Majority of the participants (57.3%) were females. Out of the 300 participants, 32% (96 individuals) don't have a definable type of job, 40 of them (13.3%) are traders, 50 of them (16.7%) are farmers while 36 of them (12.0%) are completely unemployed. Concerning the educational status of the respondents, 136 of them (45.3%) have attained tertiary education, 62 of them (20.7%) only have secondary school education, 52 of them (17.3%) have only attained primary education while 50 of them (16.7%) don't have any formal education at all. Almost all of the respondents (86.3%) are Christians, 8 of them (2.7%) represent both Muslims and African tradition practitioners. Finally, 25 of them (8.3%) don't have any religious affiliation.

These findings are similar to other research works which reported more female participants than males.^[2,4] Again, the mean age of the experimental group in this study was found to be 57.50 years. This is very similar to another study which reported the mean age of 56.7%.^[9]

The finding that women with T2DM were less likely to have abnormal ECG findings compared to men is also consistent with previous research. A large cohort study of over 9,000 patients with T2DM found that women had a lower risk of CVD than men, despite having a higher prevalence of several cardiovascular risk factors.^[10] This study suggests that there may be gender differences in the pathophysiology of CVD in patients with diabetes.

Symptoms of Ischaemic heart disease associated with type 2 diabetes in the experimental subjects.

Table 2 shows the frequency of some cardiovascular symptoms associated the age and gender of the diabetic subjects. Overall, chest discomfort was the most commonly reported symptom, with a total of 86 cases (30 male, 56 female) across all age groups. The next most common symptom was chest pain, with a total of 102 cases (34 male, 68 female). Pain in the leg was reported by 46 patients (29 male, 17 female), while Ischaemic gangrene was reported by 54 patients (21 male, 33 female). In terms of gender differences, male patients were more likely to report chest pain, pain in the leg while female patients were more likely to report chest discomfort and Ischaemic gangrene.

Also, chest pain, chest discomfort and Ischaemic gangrene were most commonly experienced by the diabetic patients within the age range of 60 years to 69 years with a frequency of 34, 30 and 18 respectively. Again, Pain anywhere else and weakness or loss of strength were most commonly associated with the age range of 80-89years, with a frequency of 8 for both conditions. Finally, the diabetic patients within the age range of 70-79 years had the highest incidence of pain in the leg, with a frequency of 12 persons.

This study suggests that there may be gender differences in the pathophysiology of CVD in patients with diabetes. Again, a study of over 500 diabetic patients found that men had a higher prevalence of left ventricular hypertrophy, a marker of heart disease, compared to women. [9] This may suggest that male diabetic patients require more aggressive screening for cardiac disease and prompt management of complications.

Glycemic and other risk factors associated with the diabetic (experimental) individuals

From table 3, it was observed that when considering the Body Mass Index (BMI), 25.3% (76 individuals) have a normal weight, 46% (138 individuals) were overweight, 26.3% (79 individuals) have obesity class 1, 1.7% (5 individuals) have obesity class 2, and 0.7% (2 individuals) have extreme obesity. Again, it was found that 86.7% (260 individuals) are non-smokers, and 13.3% (40 individuals) are smokers.

The glycemic control of the patients was established by measuring their Fasting Blood Sugar (FBS). It was found that 41.7% (125 individuals) have good glycemic control, 49.7% (149 individuals) have fair glycemic control, and 8.7% (26 individuals) have poor glycemic control.

It was revealed that 33.3% (100 individuals) have had diabetes for 1-3 years, 36.7% (110 individuals) have had diabetes for 4-6 years, and 30% (90 individuals) have had diabetes for more than 6 years. Most of the diabetic patients were found with the age range of 60-69 years.

Relationship between some parameters of the control and experimental (diabetic) groups

Table 4 presents a correlation of some cardiovascular parameters between the control and experimental (diabetic) groups. It was found that when compared with the control group, participants in the experimental group had a significantly higher age (60.58 ± 0.82 vs. 57.40 ± 0.82 years, $p = 0.01$) and BMI (29.96 ± 0.28 vs. 27.34 ± 0.19 kg/m², $p < 0.001$), with respect to

the control. However, there was no significant difference in heart rate between the groups (77.42 ± 0.87 vs. 76.97 ± 0.84 bpm, $p = 0.70$).

Again, the participants in the experimental group had significantly higher systolic blood pressure (127.83 ± 1.30 vs. 123.33 ± 1.01 mmHg, $p = 0.01$) and diastolic blood pressure (81.05 ± 0.71 vs. 77.93 ± 0.60 mmHg, $p = 0.001$) than those in the control group. Finally, fasting blood sugar levels were significantly higher in the experimental group than in the control group (5.58 ± 0.15 vs. 1.65 ± 0.01 mmol/L, $p < 0.001$)

There was a significant association between age and some of the risk factors, including systolic and diastolic blood pressure. This finding is consistent with previous studies that have shown a positive correlation between age and cardiovascular risk factors. It is important to note that this association highlights the need for early detection and management of cardiovascular risk factors in patients with type 2 diabetes, particularly those who are older.

The study also found a significant association between BMI of both the control and experimental groups, which is in line with other studies that have reported similar findings. This result emphasizes the need for weight management in patients with type 2 diabetes, which may help to reduce the risk of cardiovascular disease. The study found that there was a statistically significant positive correlation between fasting blood sugar (FBS) and BMI. This suggests that higher BMI is associated with higher fasting blood sugar levels in type 2 diabetic patients. This finding is consistent with previous research showing that obesity is a risk factor for developing type 2 diabetes and that higher BMI is associated with poorer glycemic control. The study also found that high fasting blood sugar levels were significantly associated with the presence of electrocardiographic abnormalities in type 2 diabetic patients. This finding is consistent with previous studies in Nigeria and other parts of the world. It is well-known that hyperglycemia

can lead to microvascular and macrovascular complications in diabetes, including cardiovascular disease. Therefore, effective glycemic control is essential for reducing the risk of cardiac disease in diabetic patients.

CONCLUSIONS

The current study has identified the impact of glycemic indices of known type 2 diabetics seen at the endocrine clinic in FMC, Yenagoa and its importance in controlling, preventing or reducing various cardiovascular abnormalities. The study has also shed light on the evidences of Ischaemic heart disease associated with type 2 diabetes and highlighted the need for screening for ischemic heart disease in patients with type 2 diabetes, particularly those who are older. Additionally, the study also compared between some cardiovascular variables between normal and diabetic individuals. Finally, the study has also revealed the need for gender-specific management of diabetic complications. These findings have important implications for the management of type 2 diabetes in Nigeria and other parts of Africa.

CONSENT AND ETHICAL APPROVAL

All the authors hereby declare that this experiment has been examined and approved by the appropriate ethics committee of both the Federal medical centre, Yenagoa and the university of Port Harcourt and have therefore been performed in accordance with the ethical standards laid down by both institutions. As per international standard or university standard, respondents' written consent has been collected and preserved by the authors.

REFERENCES

1. Bedane, D. A., Tadesse, S., Bariso, M., Reta, W., Desu, G. Assessment of electrocardiogram abnormality and associated factors among apparently healthy adult type 2 diabetic patients on follow-up at Jimma Medical Center, Southwest Ethiopia: Cross-sectional study. *BMC Cardiovascular Disorders*, 2021; 21(1).
2. Gupta, S., Gupta, R. K., Kulshrestha, M., Chaudhary, R. R. (2017). Evaluation of ECG

abnormalities in patients with asymptomatic type 2 diabetes mellitus. *Journal of Clinical and Diagnostic Research*, 2017;11(4).

3. Pillay, S., Hift, R., Aldous, C. A retrospective analysis of electrocardiographic abnormalities found in black South African patients with diabetes attending a regional hospital in KwaZulu-Natal. *Journal of Endocrinology, Metabolism and Diabetes of South Africa*, 2018;23(1): 9–16.
4. Gokhale, V. S., Jeyaseelan, M. P. (2020). Detailed ECG analysis in type 2 diabetes mellitus: a predictor of multitude of complications. *International Journal of Research in Medical Sciences*, 2020; 8(3): 1030.
5. Prasad, V. C., Darshan Savery, M., Vishnu Prasad, R. (2016). Cardiac autonomic dysfunction and ecg abnormalities in patients with type 2 diabetes mellitus—A comparative cross-sectional study. *National Journal of Physiology, Pharmacy and Pharmacology*, 2016; 6(3): 178–181.
6. Teimouri, K., Pakravan, S., Azadbakht, K. *The most common electrocardiographic abnormalities in patients with diabetes mellitus Mini-Review*, 2022. <https://doi.org/10.34172/jpd.2022.9142>
7. Ndour, M. A., Abdoulaye, L., Codou, F. B., Mohamed, L. Y., Nafy, N., Diaba, D. N., Aichetou, F., Alassane, M., Maboury, D., Therese, D. M. Electrocardiographic Changes in Patients with Type 2 Diabetes Multicentric Cross Sectional and Descriptive Study in Dakar. *Open Journal of Internal Medicine*, 2017; 07(03): 64–73.
8. Olamoyegun, A. M., Kolawole B. Ayodele, Ogunmola O. Olamide, Oladosu Y. Tunji. Prevalence, variants and determinants of electrocardiographic abnormalities amongst elderly Nigerians with type 2 diabetes mellitus. *International Research Journal of Medicine and Medical Sciences*, 2013; 4(8).
9. Dzudie, A., Choukem, S. P., Adam, A. K., Kengne, A. P., Gouking, P., Dehayem, M., Kamdem, F., Doualla, M. S., Joko, H. A., Lobe, M. E. E., Mbouende, Y. M., Luma, H., Mbanya, J. C., Kingue, S. Prevalence and determinants of electrocardiographic abnormalities in sub-Saharan African individuals with type 2 diabetes. *Cardiovascular Journal of Africa*, 2012;23(10): 533–537.
10. Soliman, E. Z., Backlund, J. Y. C., Bebu, I., Orchard, T. J., Zinman, B., Lachin, J. M. (2017). Electrocardiographic abnormalities and cardiovascular disease risk in type 1 diabetes: The epidemiology of diabetes interventions and complications (EDIC) study. *Diabetes Care*, 2017;40(6): 793–799.

- Abdul-Ghani, M., DeFronzo, R. A., Del Prato, S., Chilton, R., Singh, R., & Ryder, R. E. J. (2017). Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? *Diabetes Care*, *40*(7), 813–820. <https://doi.org/10.2337/dc16-2736>
- Aburishah, K., AlKheraiji, M. F., Alwalan, S. I., Isnani, A. C., Rafiullah, M., Mujammami, M., & Alfadda, A. A. (2023). Prevalence of QT prolongation and its risk factors in patients with type 2 diabetes. *BMC Endocrine Disorders*, *23*(1). <https://doi.org/10.1186/s12902-022-01235-9>
- Adeloye, D., Ige-Elegbede, J. O., Auta, A., Ale, B. M., Ezeigwe, N., Omoyele, C., Dewan, M. T., Mpazanje, R. G., Agogo, E., Alemu, W., Gadanya, M. A., Harhay, M. O., & Adebisi, A. O. (2022). Epidemiology of physical inactivity in Nigeria: A systematic review and meta-analysis. *Journal of Public Health (United Kingdom)*, *44*(3), 595–605. <https://doi.org/10.1093/pubmed/fdab147>
- Adeyemo, A. A., Zaghoul, N. A., Chen, G., Doumatey, A. P., Leitch, C. C., Hostelley, T. L., Nesmith, J. E., Zhou, J., Bentley, A. R., Shriner, D., Fasanmade, O., Okafor, G., Eghan, B., Agyenim-Boateng, K., Chandrasekharappa, S., Adeleye, J., Balogun, W., Owusu, S., Amoah, A., ... Rotimi, C. N. (2019). ZRANB3 is an African-specific type 2 diabetes locus associated with beta-cell mass and insulin response. *Nature Communications*, *10*(1). <https://doi.org/10.1038/s41467-019-10967-7>
- Adijat, O. A., Elizabeth, F., ADEJUMO, A., & ATOLAGBE James, E. (2021). The Prevalence and Risk Factors of Diabetes Mellitus among Civil Service Workers in Osogbo, Osun State, Nigeria. *Journal of Hypertension and Management*, *7*(1). <https://doi.org/10.23937/2474-3690/1510062>
- Aikaeli, F., Njim, T., Gissing, S., Moyo, F., Alam, U., Mfinanga, S. G., Okebe, J., Ramaiya, K., Webb, E. L., Jaffar, S., & Garrib, A. (2022). Prevalence of microvascular and macrovascular complications of diabetes in newly diagnosed type 2 diabetes in low-and-middle-income countries: A systematic review and meta-analysis. *PLOS Global Public Health*, *2*(6), e0000599. <https://doi.org/10.1371/journal.pgph.0000599>
- Al-Khatib, S. M., Stevenson, W. G., Ackerman, M. J., Bryant, W. J., Callans, D. J., Curtis, A. B., Deal, B. J., Dickfeld, T., Field, M. E., Fonarow, G. C., Gillis, A. M., Granger, C. B., Hammill, S. C., Hlatky, M. A., Joglar, J. A., Kay, G. N., Matlock, D. D., Myerburg, R. J., & Page, R. L. (2018). 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. *Circulation*, *138*(13), e210–e271. <https://doi.org/10.1161/CIR.0000000000000548>
- Amanat, S., Ghahri, S., Dianatinasab, A., Fararouei, M., & Dianatinasab, M. (2020). Exercise and Type 2 Diabetes. In J. Xiao (Ed.), *Physical Exercise for Human Health* (pp. 91–105). Springer Singapore. https://doi.org/10.1007/978-981-15-1792-1_6
- American Diabetes Association. (2002). Treatment of Hypertension in Adults With Diabetes. *Diabetes Care*, *25*(suppl_1), s71–s73. <https://doi.org/10.2337/diacare.25.2007.S71>

- American Diabetes Association. (2020). Cardiovascular disease and risk management: Standards of medical care in diabetes- 2020. *Diabetes Care*, *43*, S111–S134. <https://doi.org/10.2337/dc20-S010>
- American Diabetes Association. (2023). *Fats*.
- American Diabetes Association Professional Practice Committee. (2021). 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022. *Diabetes Care*, *45*(Supplement_1), S144–S174. <https://doi.org/10.2337/dc22-S010>
- Artasensi, A., Mazzolari, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2023). Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options. *Molecules*, *28*(7), 3094. <https://doi.org/10.3390/molecules28073094>
- Association, A. D. (2020). 6. Glycemic Targets: Standards of Medical Care in Diabetes—2021. *Diabetes Care*, *44*(Supplement_1), S73–S84. <https://doi.org/10.2337/dc21-S006>
- Azeez, T. A. (2021). The Ideal Insulin Resistance Index for Cardiovascular Risk Discrimination in Type 2 Diabetes Mellitus. *SN Comprehensive Clinical Medicine*, *4*(1), 9. <https://doi.org/10.1007/s42399-021-01101-0>
- Balbi, M. E., Tonin, F. S., Mendes, A. M., Borba, H. H., Wiens, A., Fernandez-Llimos, F., & Pontarolo, R. (2018). Antioxidant effects of vitamins in type 2 diabetes: a meta-analysis of randomized controlled trials. *Diabetology & Metabolic Syndrome*, *10*(1), 18. <https://doi.org/10.1186/s13098-018-0318-5>
- Balint, B., Jepchumba, V. K., Guéant, J.-L., & Guéant-Rodriguez, R.-M. (2020). Mechanisms of homocysteine-induced damage to the endothelial, medial and adventitial layers of the arterial wall. *Biochimie*, *173*, 100–106. <https://doi.org/https://doi.org/10.1016/j.biochi.2020.02.012>
- Basu, A., Jenkins, A. J., Stoner, J. A., Thorpe, S. R., Klein, R. L., Lopes-Virella, M. F., Garvey, W. T., & Lyons, T. J. (2014). Plasma total homocysteine and carotid intima-media thickness in type 1 diabetes: A prospective study. *Atherosclerosis*, *236*(1). <https://doi.org/10.1016/j.atherosclerosis.2014.07.001>
- Bays, H. E., Bindlish, S., & Clayton, T. L. (2023). Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023. *Obesity Pillars*, *5*, 100056. <https://doi.org/https://doi.org/10.1016/j.obpill.2023.100056>
- Beckman, J. A., Creager, M. A., & Libby, P. (2002). Diabetes and atherosclerosis epidemiology, pathophysiology, and management. In *Journal of the American Medical Association* (Vol. 287, Issue 19, pp. 2570–2581). American Medical Association. <https://doi.org/10.1001/jama.287.19.2570>
- Bonow, R., Mann, D., Zipes, D., & Libby, P. (2011). *Baraunwald's Heart Disease: A textbook of cardiovascular medicine* (5th ed.). Elsevier Science.

- Boulé, N. G., Haddad, E., Kenny, G. P., Wells, G. A., & Sigal, R. J. (2001). Effects of Exercise on Glycemic Control and Body Mass in Type 2 Diabetes Mellitus: A Meta-analysis of Controlled Clinical Trials. *JAMA*, 286(10), 1218–1227. <https://doi.org/10.1001/jama.286.10.1218>
- Buse, J. B., Friedewald, W. T., Bigger, J. T., Byington, R. P., Cushman, W. C., Genuth, S., Gerstein, H. C., Ginsberg, H. N., Goff, D. C., Grimm, R. H., Probstfield, J. L., Simons-Morton, D. G., Russo, R., Thompson, K., Cukierman-Yaffe, T., Gafni, A., Shamis, I., Shehadeh, N., Tadeson, B., ... Cooper, L. S. (2007). Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: Design and methods. *American Journal of Cardiology*, 99(12). <https://doi.org/10.1016/j.amjcard.2007.03.003>
- Buse, J., Polonsky, K., & Burant, C. (2008). Type 2 Diabetes mellitus. In Kronenberg, H. M., Melmed, S., Larsen and P.R.,. *Williams Textbook of Endocrinology*, 1329–1389.
- Cai, Z., Yuan, S., Zhong, Y., Deng, L., Li, J., Tan, X., & Feng, J. (2021). Amelioration of Endothelial Dysfunction in Diabetes: Role of Takeda G Protein–Coupled Receptor 5. In *Frontiers in Pharmacology* (Vol. 12). Frontiers Media S.A. <https://doi.org/10.3389/fphar.2021.637051>
- Carnethon, M. R., Prineas, R. J., Temprosa, M., Zhang, Z.-M., Uwaifo, G., Molitch, M. E., & Group, for the D. P. P. R. (2006). The Association Among Autonomic Nervous System Function, Incident Diabetes, and Intervention Arm in the Diabetes Prevention Program. *Diabetes Care*, 29(4), 914–919. <https://doi.org/10.2337/diacare.29.04.06.dc05-1729>
- Centres for Disease control and prevention. (n.d.). *LDL and HDL Cholesterol and Triglyceride*.
- Ceriello, A. (2005). Postprandial Hyperglycemia and Diabetes Complications: Is It Time to Treat? *Diabetes*, 54(1), 1–7. <https://doi.org/10.2337/diabetes.54.1.1>
- Chen, F., Wang, J., Chen, X., Yu, L., An, Y., Gong, Q., Chen, B., Xie, S., Zhang, L., Shuai, Y., Zhao, F., Chen, Y., Li, G., & Zhang, B. (2023). Development of models to predict 10-30-year cardiovascular disease risk using the Da Qing IGT and diabetes study. *Diabetology & Metabolic Syndrome*, 15(1), 62. <https://doi.org/10.1186/s13098-023-01039-4>
- Cheng, Y. J., Kanaya, A. M., Araneta, M. R. G., Saydah, S. H., Kahn, H. S., Gregg, E. W., Fujimoto, W. Y., & Imperatore, G. (2019). Prevalence of Diabetes by Race and Ethnicity in the United States, 2011-2016. *JAMA - Journal of the American Medical Association*, 322(24), 2389–2398. <https://doi.org/10.1001/jama.2019.19365>
- Chivese, T., Norris, S. A., & Levitt, N. S. (2019). Progression to type 2 diabetes mellitus and associated risk factors after hyperglycemia first detected in pregnancy: A cross-sectional study in Cape Town, South Africa. *PLOS Medicine*, 16(9), e1002865-. <https://doi.org/10.1371/journal.pmed.1002865>
- Colberg, S. R., Sigal, R. J., Yardley, J. E., Riddell, M. C., Dunstan, D. W., Dempsey, P. C., Horton, E. S., Castorino, K., & Tate, D. F. (2016). Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. *Diabetes Care*, 39(11), 2065–2079. <https://doi.org/10.2337/dc16-1728>

- Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., Huikuri, H. V., Johansson, I., Juni, P., Lettino, M., Marx, N., Mellbin, L. G., Ostgren, C. J., Rocca, B., Roffi, M., ... Chowdhury, T. A. (2020). 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *European Heart Journal*, *41*(2), 255–323. <https://doi.org/10.1093/eurheartj/ehz486>
- Dal Canto, E., Ceriello, A., Rydén, L., Ferrini, M., Hansen, T. B., Schnell, O., Standl, E., & Beulens, J. W. J. (2019). Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. *European Journal of Preventive Cardiology*, *26*(2_suppl), 25–32. <https://doi.org/10.1177/2047487319878371>
- Davey, P. P., Barlow, C., & Hart, C. (1979). Prolongation of the QT interval in heart failure occurs at low but not high heart rate. *Clinical Science*, *98*(5), 603–610.
- de Leiva, A. (2003). Hyperhomocysteinemia as Cardiovascular Risk Factor in Type 2 Diabetes Mellitus. In N. Hâncu (Ed.), *Cardiovascular Risk in Type 2 Diabetes Mellitus: Assessment and Control* (pp. 173–180). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-59352-9_15
- Derosa, G., & Maffioli, P. (2010). Effects of Thiazolidinediones and Sulfonylureas in Patients with Diabetes. *Diabetes Technology & Therapeutics*, *12*(6), 491–501. <https://doi.org/10.1089/dia.2009.0172>
- Dunya, T., Jedidiah, I. M., Agus, S., & Meda, E. P. (2022). Lifetime risk, life expectancy, and year lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study. *The Lancet. Diabetes & Endocrinology*, *10*(11), 795–803. [https://doi.org/10.1016/S2213-8587\(22\)00252-2](https://doi.org/10.1016/S2213-8587(22)00252-2)
- Dyson, P. (2015). Low Carbohydrate Diets and Type 2 Diabetes: What is the Latest Evidence? In *Diabetes Therapy* (Vol. 6, Issue 4, pp. 411–424). Springer Healthcare. <https://doi.org/10.1007/s13300-015-0136-9>
- Dzudie, A., Choukem, S. P., Adam, A. K., Kengne, A. P., Gouking, P., Dehayem, M., Kamdem, F., Doualla, M. S., Joko, H. A., Lobe, M. E. E., Mbouende, Y. M., Luma, H., Mbanya, J. C., & Kingue, S. (2012). Prevalence and determinants of electrocardiographic abnormalities in sub-Saharan African individuals with type 2 diabetes. *Cardiovascular Journal of Africa*, *23*(10), 533–537. <https://doi.org/10.5830/CVJA-2012-054>
- Eichner, J. E., Wang, W., Zhang, Y., Lee, E. T., & Welty, T. K. (2010). Tobacco use and cardiovascular disease among American Indians: The strong heart study. *International Journal of Environmental Research and Public Health*, *7*(10), 3816–3830. <https://doi.org/10.3390/ijerph7103816>
- Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018). Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in

2007-2017. In *Cardiovascular Diabetology* (Vol. 17, Issue 1). BioMed Central Ltd. <https://doi.org/10.1186/s12933-018-0728-6>

- Elric, Z., & Micheal Roden. (2019). GLP-1 receptor agonists and cardiovascular disease: drug-specific or class effects? *The Lancet Diabetes & Endocrinology*, 7(2), 89–90.
- Estruch, R., Martínez-González, M. Á., Corella, D., Salas-Salvadó, J., Ruiz-Gutiérrez, V., Covas, M. I., Fiol, M., Gómez-Gracia, E., López-Sabater, M. C., Vinyoles, E., Arós, F., Conde, M., Lahoz, C., Lapetra, J., Sáez, G., & Ros, E. (2006). Effects of a Mediterranean-Style Diet on Cardiovascular Risk Factors. *Annals of Internal Medicine*, 145(1), 1–11. <https://doi.org/10.7326/0003-4819-145-1-200607040-00004>
- Fagan, T. C., & Sowers, J. (1999). Type 2 Diabetes Mellitus: Greater Cardiovascular Risks and Greater Benefits of Therapy. *Archives of Internal Medicine*, 159(10), 1033–1034. <https://doi.org/10.1001/archinte.159.10.1033>
- Fagard, R. H. (2009). Smoking amplifies cardiovascular risk in patients with hypertension and diabetes. In *Diabetes care: Vol. 32 Suppl 2*. <https://doi.org/10.2337/dc09-s354>
- Fardoun, R. Z. (2007). The Use of Vitamin E in Type 2 Diabetes Mellitus. *Clinical and Experimental Hypertension*, 29(3), 135–148. <https://doi.org/10.1080/10641960701361601>
- Feingold, K. R., Anwalt, B., & Blackman, M. R. (2020). Dyslipidemia in diabetes. In *Endotext[internet]*. MDtext.com,Inc.
- Fiorentino, T. V., Prioletta, A., Zuo, P., & Folli, F. (2013). Hyperglycemia-induced Oxidative Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases. In *Current Pharmaceutical Design* (Vol. 19).
- Forouhi, N. G., & Wareham, N. J. (2014). Epidemiology of diabetes. *Medicine (Abingdon, England : UK Ed.)*, 42(12), 698–702. <https://doi.org/10.1016/j.mpmed.2014.09.007>
- Gami, A., Witt, B., Howard, D., Erwin, P., Gami, L., Somers, V., & Montori, V. (2007). Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VMMetabolic syndrome and the risk of incident cardiovascular events and death: a systematic reviewand meta-analysis of longitudinal studies. *J Am Coll Cardiol* 49: 403-414. *Journal of the American College of Cardiology*, 49, 403–414. <https://doi.org/10.1016/j.jacc.2006.09.032>
- Giugliano, D., Scappaticcio, L., Longo, M., Bellastella, G., & Esposito, K. (2021). GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off. *Cardiovascular Diabetology*, 20(1), 205. <https://doi.org/10.1186/s12933-021-01400-9>
- Gokhale, V. S., & Jeyaseelan, M. P. (2020). Detailed ECG analysis in type 2 diabetes mellitus: a predictor of multitude of complications. *International Journal of Research in Medical Sciences*, 8(3), 1030. <https://doi.org/10.18203/2320-6012.ijrms20200775>
- Gupta, S., Gupta, R. K., Kulshrestha, M., & Chaudhary, R. R. (2017). Evaluation of ECG abnormalities in patients with asymptomatic type 2 diabetes mellitus. *Journal of Clinical and Diagnostic Research*, 11(4), OC39–OC41. <https://doi.org/10.7860/JCDR/2017/24882.9740>

- Harms, P. P., van der Heijden, A. A., Rutters, F., Tan, H. L., Beulens, J. W. J., Nijpels, G., & Elders, P. (2021). Prevalence of ECG abnormalities in people with type 2 diabetes: The Hoorn Diabetes Care System cohort. *Journal of Diabetes and Its Complications*, 35(2). <https://doi.org/10.1016/j.jdiacomp.2020.107810>
- Held, C., White, H. D., Stewart, R. A. H., Budaj, A., Cannon, C. P., Hochman, J. S., Koenig, W., Siegbahn, A., Steg, P. G., Soffer, J., Weaver, W. D., Östlund, O., & Wallentin, L. (2017). Inflammatory biomarkers interleukin-6 and c-reactive protein and outcomes in stable coronary heart disease: Experiences from the STABILITY (stabilization of atherosclerotic plaque by initiation of darapladib therapy) trial. *Journal of the American Heart Association*, 6(10). <https://doi.org/10.1161/JAHA.116.005077>
- Henry, R. R. (2001). Preventing Cardiovascular Complications of Type 2 Diabetes: Focus on Lipid Management. *Clinical Diabetes*, 19(3), 113–120. <https://doi.org/10.2337/diaclin.19.3.113>
- Homocysteine Collaboration Studies. (2002). Homocysteine and Risk of Ischemic Heart Disease and Stroke A Meta-analysis. *JAMA*, 288(16), 2015–2022. <https://doi.org/10.1001/jama.288.16.2015>
- Hoogeveen, E. K., Kostense, P. J., Jakobs, C., Dekker, J. M., Nijpels, G., Heine, R. J., Bouter, L. M., & Stehouwer, C. DA. (2000). *Hyperhomocysteinemia Increases Risk of Death, Especially in Type 2 Diabetes 5-Year Follow-Up of the Hoorn Study*. <http://www.circulationaha.org>
- Hooi, J. D., Kester, A. D. M., Stoffers, H. E. J. H., Overdijk, M. M., van Ree, J. W., & Knottnerus, J. A. (2001). Incidence of and Risk Factors for Asymptomatic Peripheral Arterial Occlusive Disease: A Longitudinal Study. *American Journal of Epidemiology*, 153(7), 666–672. <https://doi.org/10.1093/aje/153.7.666>
- Hu, F. B., Stampfer, M. J., Colditz, G. A., Ascherio, A., Rexrode, K. M., Willett, W. C., & Manson, J. E. (2000). Physical Activity and Risk of Stroke in Women. *JAMA*, 283(22), 2961–2967. <https://doi.org/10.1001/jama.283.22.2961>
- Hubert, H. B., Mcnamara, P. M., & Castelli, W. P. (1983). *Obesity as an Independent Risk Factor for Cardiovascular Disease: A 26-year Follow-up of Participants in the Framingham Heart Study*. <http://ahajournals.org>
- Huebschmann, A. G., Huxley, R. R., Kohrt, W. M., Zeitler, P., Regensteiner, J. G., & Reusch, J. E. B. (2019). Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course. In *Diabetologia* (Vol. 62, Issue 10, pp. 1761–1772). Springer Verlag. <https://doi.org/10.1007/s00125-019-4939-5>
- Hwang, Y. C., Ahm, H. Y., Yu, S. H., Park, S. W., & Park, C. Y. (2014). Atherogenic dyslipidaemic profiles associated with the development of type 2 diabetes: a 3.1 year longitudinal study. *Diabetic Medicine: A Journal of the British Diabetic Association*, 31(1), 24–30.
- Jia, G., Hill, M. A., & Sowers, J. R. (2018). Diabetic cardiomyopathy: An update of mechanisms contributing to this clinical entity. In *Circulation Research* (Vol. 122, Issue 4, pp. 624–638). Lippincott Williams and Wilkins. <https://doi.org/10.1161/CIRCRESAHA.117.311586>

- Jimenez-Quevedo, P., Brugaletta, S., Cequier, A., Iñiguez, A., Serra, A., Mainar, V., Campo, G., Tespili, M., Nombela-Franco, L., del Trigo, M., Gonzalo, N., Escaned, J., Salinas, P., Nuñez-Gil, I., Fernandez-Perez, C., Fernández-Ortiz, A., Macaya, C., Serruys, P. W., & Sabate Tenas, M. (2019). Long-term impact of diabetes in patients with ST-segment elevation myocardial infarction: Insights from the EXAMINATION randomized trial. *Catheterization and Cardiovascular Interventions*, *94*(7), 917–925. <https://doi.org/10.1002/ccd.28194>
- Jørgensen, P. G., Jensen, M. T., Mogelvang, R., Von Scholten, B. J., Bech, J., Fritz-Hansen, T., Galatius, S., Biering-Sørensen, T., Andersen, H. U., Vilsbøll, T., Rossing, P., & Jensen, J. S. (2016). Abnormal echocardiography in patients with type 2 diabetes and relation to symptoms and clinical characteristics. *Diabetes and Vascular Disease Research*, *13*(5), 321–330. <https://doi.org/10.1177/1479164116645583>
- Katheria, R., Setty, S. K., Arun, B. S., Bhat, P., Jagadeesh, H. V, & Manjunath, C. N. (2021). Significance of ‘recovery ST-segment depression’ in exercise stress test. *Indian Heart Journal*, *73*(6), 693–696. <https://doi.org/10.1016/j.ihj.2021.10.001>
- Kaze, A. D., Santhanam, P., Musani, S. K., Ahima, R., & Echouffo-Tcheugui, J. B. (2021). Metabolic dyslipidemia and cardiovascular outcomes in type 2 diabetes mellitus: Findings from the look ahead study. *Journal of the American Heart Association*, *10*(7). <https://doi.org/10.1161/JAHA.120.016947>
- Khaire, U., SHinde, S., & Bhattacharya. (2018). A study of ECG and 2D echo findings in type 2 Diabetes Mellitus patients. *International Journal of Science and Research*, *7*(2), 327–334.
- Khan, M. A. B., Hashim, M. J., King, J. K., Govender, R. D., Mustafa, H., & Kaabi, J. Al. (2020). Epidemiology of Type 2 diabetes - Global burden of disease and forecasted trends. *Journal of Epidemiology and Global Health*, *10*(1), 107–111. <https://doi.org/10.2991/JEGH.K.191028.001>
- Khan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., Kosiborod, M. N., & Butler, J. (2020). Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. *Circulation*, *142*(12), 1205–1218. <https://doi.org/10.1161/CIRCULATIONAHA.120.045888>
- Khan, N. K., Goode, K. M., Cleland, J. G. F., Rigby, A. S., Freemantle, N., Eastaugh, J., Clark, A. L., de Silva, R., Calvert, M. J., Swedberg, K., Komajda, M., Mareev, Vi., & Follath, F. (2007). Prevalence of ECG abnormalities in an international survey of patients with suspected or confirmed heart failure at death or discharge. *European Journal of Heart Failure*, *9*(5), 491–501. <https://doi.org/10.1016/j.ejheart.2006.11.003>
- King, D. E., Mainous III, A. G., Buchanan, T. A., & Pearson, W. S. (2003). C-Reactive Protein and Glycemic Control in Adults With Diabetes. *Diabetes Care*, *26*(5), 1535–1539. <https://doi.org/10.2337/diacare.26.5.1535>

- Kittnar, O. (2015). Electrocardiographic changes in diabetes mellitus. In *Physiological Research* (Vol. 64, pp. S559–S566). Czech Academy of Sciences. <https://doi.org/10.33549/physiolres.933230>
- Kumar, A., Singh, V., & Kumar Bayfront, A. (2010). Vascular Health and Risk Management Dovepress Atherogenic dyslipidemia and diabetes mellitus: what's new in the management arena? In *Vascular Health and Risk Management*. <https://www.dovepress.com/>
- Kutkiene, S., Petrulioniene, Z., Laucevicius, A., Matuzeviciene, G., Kasiulevicius, V., Petrulionyte, E., Staigyte, J., Saulyte, A., Gargalskaite, U., Skiauteryte, E., Kovaite, M., & Rinkuniene, E. (2018). Cardiovascular risk profile of patients with atherogenic dyslipidemia in middle age Lithuanian population. *Lipids in Health and Disease*, 17(1). <https://doi.org/10.1186/s12944-018-0851-0>
- Laakso, M. (1999). Hyperglycemia and cardiovascular disease in type 2 diabetes. *Diabetes*, 48(5), 937–942. <https://doi.org/10.2337/diabetes.48.5.937>
- Lawrence, J. M., Divers, J., Isom, S., Saydah, S., Imperatore, G., Pihoker, C., Marcovina, S. M., Mayer-Davis, E. J., Hamman, R. F., Dolan, L., Dabelea, D., Pettitt, D. J., Liese, A. D., & Group, S. for D. in Y. S. (2021). Trends in Prevalence of Type 1 and Type 2 Diabetes in Children and Adolescents in the US, 2001-2017. *JAMA*, 326(8), 717–727. <https://doi.org/10.1001/jama.2021.11165>
- Levy, D. (1988). Left Ventricular Hypertrophy. *Drugs*, 35(5), 1–5. <https://doi.org/10.2165/00003495-198800355-00002>
- Libby, P., Ridker, P. M., & Maseri, A. (2002). Inflammation and atherosclerosis. *Circulation*, 105(9), 1135–1143. <https://doi.org/10.1161/hc0902.104353>
- Lin, X., Xu, Y., Pan, X., Xu, J., Ding, Y., Sun, X., Song, X., Ren, Y., & Shan, P. F. (2020). Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. *Scientific Reports*, 10(1). <https://doi.org/10.1038/s41598-020-71908-9>
- Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016). Clinical update: Cardiovascular disease in diabetes mellitus. In *Circulation* (Vol. 133, Issue 24, pp. 2459–2502). Lippincott Williams and Wilkins. <https://doi.org/10.1161/CIRCULATIONAHA.116.022194>
- Ma, C. X., Ma, X. N., Guan, C. H., Li, Y. D., Mauricio, D., & Fu, S. B. (2022). Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. In *Cardiovascular Diabetology* (Vol. 21, Issue 1). BioMed Central Ltd. <https://doi.org/10.1186/s12933-022-01516-6>
- Malik, S., Wong, N. D., Franklin, S. S., Kamath, T. V., L'Italien, G. J., Pio, J. R., & Williams, G. R. (2004). Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. *Circulation*, 110(10), 1245–1250. <https://doi.org/10.1161/01.CIR.0000140677.20606.0E>

- Mancusi, C., Izzo, R., di Gioia, G., Losi, M. A., Barbato, E., & Morisco, C. (2020). Insulin Resistance the Hinge Between Hypertension and Type 2 Diabetes. *High Blood Pressure & Cardiovascular Prevention*, 27(6), 515–526. <https://doi.org/10.1007/s40292-020-00408-8>
- Mapanga, R. F., & Faadiel Essop, M. (2016). First published October 30. *Am J Physiol Heart Circ Physiol*, 310, 153–173. <https://doi.org/10.1152/ajpheart.00206.2015>.-The
- Márquez-Espinoza, A., Mercado-Rojas, J. G., Vega-Martínez, G., & Alvarado-Serrano, C. (2011). ECG Ambulatory System for Long Term Monitoring of Heart Rate Dynamics. In F. Silviu (Ed.), *Practical Applications and Solutions Using LabVIEW™ Software*. IntechOpen. <https://doi.org/10.5772/20946>
- Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016). Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes. *Annals of Internal Medicine*, 164(11), 740–751. <https://doi.org/10.7326/M15-2650>
- Mason, S. A., Keske, M. A., & Wadley, G. D. (2021). Effects of Vitamin C Supplementation on Glycemic Control and Cardiovascular Risk Factors in People With Type 2 Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis of Randomized Controlled Trials. *Diabetes Care*, 44(2), 618–630. <https://doi.org/10.2337/dc20-1893>
- Meek, S., & Morris, F. (2002). Introduction. ILeads, rate, rhythm, and cardiac axis. *BMJ*, 324(7334), 415–418. <https://doi.org/10.1136/bmj.324.7334.415>
- Mohamed, S. F., Mwangi, M., Mutua, M. K., Kibachio, J., Hussein, A., Ndegwa, Z., Owondo, S., Asiki, G., & Kyobutungi, C. (2018). Prevalence and factors associated with pre-diabetes and diabetes mellitus in Kenya: Results from a national survey. *BMC Public Health*, 18. <https://doi.org/10.1186/s12889-018-6053-x>
- Mohan, V., Vassy, J. L., Pradeepa, R., Deepa, M., & Subashim, S. (2010). The Indian type 2 diabetes risk score also helps identify those at risk of macrovascular disease and neuropathy (CURES - 7). *The Journal of the Association of Physicians of India*, 59, 430–433.
- Mooradian, A. D., Haas, M. J., Wehmeier, K. R., & Wong, N. C. W. (2008). Obesity-related changes in high-density lipoprotein metabolism. In *Obesity* (Vol. 16, Issue 6, pp. 1152–1160). <https://doi.org/10.1038/oby.2008.202>
- Motala, A. A., Mbanya, J. C., Ramaiya, K., Pirie, F. J., & Ekoru, K. (2022). Type 2 diabetes mellitus in sub-Saharan Africa: challenges and opportunities. *Nature Reviews Endocrinology*, 18(4), 219–229. <https://doi.org/10.1038/s41574-021-00613-y>
- Mould, S. J., Soliman, E. Z., Bertoni, A. G., Bhave, P. D., Yeboah, J., & Singleton, M. J. (2021). Association of T-wave abnormalities with major cardiovascular events in diabetes: the ACCORD trial to Control Cardiovascular Risk in Diabetes CHF Congestive heart failure MC Minnesota Code NRI Net reclassification improvement RI Reclassification index ROC Receiver operating characteristic TWA T-wave abnormalities UKPDS UK Prospective Diabetes Study. *Diabetologia*, 504–511. <https://doi.org/10.1007/s00125-020-05337-8>/Published

- Musunuru, K. (2010). Atherogenic Dyslipidemia: Cardiovascular Risk and Dietary Intervention. *Lipids*, 45(10), 907–914. <https://doi.org/10.1007/s11745-010-3408-1>
- Narindrarangkura, P., Bosl, W., Rangsin, R., & Hatthachote, P. (2019). Prevalence of dyslipidemia associated with complications in diabetic patients: A nationwide study in Thailand. *Lipids in Health and Disease*, 18(1). <https://doi.org/10.1186/s12944-019-1034-3>
- Ndour, M. A., Abdoulaye, L., Codou, F. B., Mohamed, L. Y., Nafy, N., Diaba, D. N., Aichetou, F., Alassane, M., Maboury, D., & Therese, D. M. (2017). Electrocardiographic Changes in Patients with Type 2 Diabetes Multicentric Cross Sectional and Descriptive Study in Dakar. *Open Journal of Internal Medicine*, 07(03), 64–73. <https://doi.org/10.4236/ojim.2017.73007>
- Nijpels, G., Van Der Heijden, A. A. W. A., Elders, P., Beulens, J. W. J., & De Vet, H. C. W. (2021). The interobserver agreement of ECG abnormalities using Minnesota codes in people with type 2 diabetes. *PLoS ONE*, 16(8 August). <https://doi.org/10.1371/journal.pone.0255466>
- Nyenwe, E., Odia, O., Ihekweba, A., Ojule, A., & Babatunde, S. (2003). Type 2 diabetes in Adult Nigerians: A study of its prevalence and risk factors in Port Harcourt, Nigeria. *Diabetes Research and Clinical Practice*, 62, 177–185. <https://doi.org/10.1016/j.diabres.2003.07.002>
- Ogbera, A. O., & Ekpebegh, C. (2014). Diabetes mellitus in Nigeria: The past, present and future. *World Journal of Diabetes*, 5(6), 905. <https://doi.org/10.4239/wjd.v5.i6.905>
- Olamoyegun, A. M., Kolawole B. Ayodele, Ogunmola O. Olamide, & Oladosu Y. Tunji. (2013). Prevalence, variants and determinants of electrocardiographic abnormalities amongst elderly Nigerians with type 2 diabetes mellitus. *International Research Journal of Medicine and Medical Sciences*, 4(8). <https://doi.org/10.14303/jmms.2013.107>
- Oliver, E., McGillicuddy, F., Phillips, C., Toomey, S., & Roche, H. M. (2010). The role of inflammation and macrophage accumulation in the development of obesity-induced type 2 diabetes mellitus and the possible therapeutic effects of long-chain n-3 PUFA. *Proceedings of the Nutrition Society*, 69(2), 232–243. <https://doi.org/DOI:10.1017/S0029665110000042>
- Pappachan, J. M., Sebastian, J., Bino, B. C., Jayaprakash, K., Vijayakumar, K., Sujathan, P., & Adinegara, L. A. (2008). Cardiac autonomic neuropathy in diabetes mellitus: prevalence, risk factors and utility of corrected QT interval in the ECG for its diagnosis. *Postgraduate Medical Journal*, 84(990), 205. <https://doi.org/10.1136/pgmj.2007.064048>
- Pappan, N., & Rehman, A. (2022). *Dyslipidemia*. Statpearls.
- Pederson, O., & Gaede, P. (2003). Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study. *Metabolism: Clinical and Experimental*, 52(8), 19–23.
- Penckofer, S., Schwertz, D., & Florczak, K. (2002). Oxidative Stress and Cardiovascular Disease in Type 2 Diabetes: The Role of Antioxidants and Pro-Oxidants. *Journal of Cardiovascular Nursing*, 16(2). https://journals.lww.com/jcnjournal/Fulltext/2002/01000/Oxidative_Stress_and_Cardiovascular_Disease_in.7.aspx

- Pérez, P. A., Ybarra Muñoz, J., Blay Cortés, V., & de Pablos Velasco, P. (2007). Obesity and cardiovascular disease. *Public Health Nutrition*, *10*(10A), 1156–1163. <https://doi.org/DOI:10.1017/S1368980007000651>
- Petrie, J. R., Guzik, T. J., & Touyz, R. M. (2018). Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. In *Canadian Journal of Cardiology* (Vol. 34, Issue 5, pp. 575–584). Elsevier Inc. <https://doi.org/10.1016/j.cjca.2017.12.005>
- Pillay, S., Hift, R., & Aldous, C. (2018). A retrospective analysis of electrocardiographic abnormalities found in black South African patients with diabetes attending a regional hospital in KwaZulu-Natal. *Journal of Endocrinology, Metabolism and Diabetes of South Africa*, *23*(1), 9–16. <https://doi.org/10.1080/16089677.2017.1385965>
- Platt, D. E., Hariri, E., Salameh, P., Merhi, M., Sabbah, N., Helou, M., Mouzaya, F., Nemer, R., Al-Sarraj, Y., El-Shanti, H., Abchee, A. B., & Zalloua, P. A. (2017). Type II diabetes mellitus and hyperhomocysteinemia: a complex interaction. *Diabetology & Metabolic Syndrome*, *9*(1), 19. <https://doi.org/10.1186/s13098-017-0218-0>
- Pop-Busui, R. (2010). Cardiac Autonomic Neuropathy in Diabetes: A clinical perspective. *Diabetes Care*, *33*(2), 434–441. <https://doi.org/10.2337/dc09-1294>
- Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J. P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., & St-Onge, M. P. (2021). Obesity and Cardiovascular Disease A Scientific Statement From the American Heart Association. In *Circulation* (Vol. 143, Issue 21, pp. E984–E1010). Lippincott Williams and Wilkins. <https://doi.org/10.1161/CIR.0000000000000973>
- Prasad, V. C., Darshan Savery, M., & Vishnu Prasad, R. (2016). Cardiac autonomic dysfunction and ecg abnormalities in patients with type 2 diabetes mellitus—A comparative cross-sectional study. *National Journal of Physiology, Pharmacy and Pharmacology*, *6*(3), 178–181. <https://doi.org/10.5455/njppp.2016.6.27122015107>
- Qiu, Z., Chen, X., Geng, T., Wan, Z., Lu, Q., Li, L., Zhu, K., Zhang, X., Liu, Y., Lin, X., Chen, L., Shan, Z., Liu, L., Pan, A., & Liu, G. (2022). Associations of Serum Carotenoids With Risk of Cardiovascular Mortality Among Individuals With Type 2 Diabetes: Results From NHANES. *Diabetes Care*, *45*(6), 1453–1461. <https://doi.org/10.2337/dc21-2371>
- Rasaki, S. O., Kasali, F. O., Biliaminu, S. A., Odeigah, L. O., Sunday, A. A., Sule, A. G., & Musah, Y. (2017). Prevalence of diabetes and pre-diabetes in Oke-Ogun region of Oyo State, Nigeria. *Cogent Medicine*, *4*(1), 1326211. <https://doi.org/10.1080/2331205x.2017.1326211>
- Rautaharju, P. M., Surawicz, B., & Gettes, L. S. (2009). AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: Part IV: The ST segment, t and u waves, and the QT interval: A scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; The American College of Cardiology Foundation. In *Circulation* (Vol. 119, Issue 10). <https://doi.org/10.1161/CIRCULATIONAHA.108.191096>

- Reaven, G. (2005). Insulin resistance, type 2 diabetes mellitus, and cardiovascular disease: The end of the beginning. In *Circulation* (Vol. 112, Issue 20, pp. 3030–3032). <https://doi.org/10.1161/CIRCULATIONAHA.105.504670>
- Rick Ansorge. (2022). *Plant-Based Diet for Heart Health*. Webmed.
- Rodriguez-Gutierrez, R., Gonzalez-Gonzalez, J. G., Zuñiga-Hernandez, J. A., & McCoy, R. G. (2019). Benefits and harms of intensive glycemic control in patients with type 2 diabetes. *BMJ*, 367, 15887. <https://doi.org/10.1136/bmj.15887>
- Rodríguez-Gutiérrez, R., & Montori, V. M. (2016). Glycemic control for patients with type 2 diabetes mellitus: Our evolving faith in the face of evidence. *Circulation: Cardiovascular Quality and Outcomes*, 9(5), 504–512. <https://doi.org/10.1161/CIRCOUTCOMES.116.002901>
- Rolfe, M. (1988). Research from the South Macrovascular disease in diabetics in Central Africa. In *BRITISH MEDICAL JOURNAL* (Vol. 296).
- Romesh, K. (2023, January 24). *Type 2 Diabetes Mellitus Treatment & Management*. Medscape. [emedicine.medscape.com/article/117853-treatment](https://www.emedicine.medscape.com/article/117853-treatment)
- Sabir, A., Balarabe, S., Sani, A., Isezuo, S., Bello, K., Jimoh, A., & Iwuala, S. (2017). Prevalence of diabetes mellitus and its risk factors among the suburban population of Northwest Nigeria. *Sahel Medical Journal*, 20(4), 168. https://doi.org/10.4103/smj.smj_47_16
- Sardesai, V., Kokane, H., Mukherjee, S., & Sangle, S. (2022). A study of electrocardiographic and 2D echocardiographic changes in type 2 diabetes mellitus patients without cardiovascular symptoms. *Journal of Family Medicine and Primary Care*, 11, 1036. https://doi.org/10.4103/jfmpc.jfmpc_1195_21
- Schmidt, A. M. (2019). Diabetes Mellitus and Cardiovascular Disease. In *Arteriosclerosis, thrombosis, and vascular biology* (Vol. 39, Issue 4, pp. 558–568). NLM (Medline). <https://doi.org/10.1161/ATVBAHA.119.310961>
- Seferović, P. M., & Paulus, W. J. (2015). Clinical diabetic cardiomyopathy: A two-faced disease with restrictive and dilated phenotypes. In *European Heart Journal* (Vol. 36, Issue 27, pp. 1718–1727). Oxford University Press. <https://doi.org/10.1093/eurheartj/ehv134>
- Seftel, H., & Walker, A. (1966). Vascular disease in South African Bantu diabetics. *Diabetologia*, 2(4), 286–290.
- Sellers, M. B., Divers, J., Lu, L., Xu, J., Smith, S. C., Bowden, D. W., Herrington, D., Freedman, B. I., & Soliman, E. Z. (2014). Prevalence and determinants of electrocardiographic abnormalities in African Americans with type 2 diabetes. *Journal of Epidemiology and Global Health*, 4(4), 289–296. <https://doi.org/10.1016/j.jegh.2014.04.003>
- Serhiyenko, V. A., & Serhiyenko, A. A. (2018). Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment. *World Journal of Diabetes*, 9(1), 1–24. <https://doi.org/10.4239/wjd.v9.i1.1>

- Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010). Global estimates of the prevalence of diabetes for 2010 and 2030. In *Diabetes Research and Clinical Practice* (Vol. 87, Issue 1, pp. 4–14). <https://doi.org/10.1016/j.diabres.2009.10.007>
- Simmons, R. K., Coleman, R. L., Price, H. C., Holman, R. R., Khaw, K.-T., Wareham, N. J., & Griffin, S. J. (2008). Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort. *Diabetes Care*, *32*(4), 708–713. <https://doi.org/10.2337/dc08-1918>
- Sinamaw, D., Getnet, M., Abdulkadir, M., Abebaw, K., Ebrahim, M., Diress, M., Akalu, Y., Ambelu, A., & Dagnew, B. (2022). Patterns and associated factors of electrocardiographic abnormality among type 2 diabetic patients in Amhara National Regional State Referral Hospitals, Ethiopia: a multicenter institution-based cross-sectional study. *BMC Cardiovascular Disorders*, *22*(1). <https://doi.org/10.1186/s12872-022-02661-2>
- Sodi, R., McKay, K., Dampetla, S., & Pappachan, J. M. (2018). Monitoring glycaemic control in patients with diabetes mellitus. *BMJ*, *363*, k4723. <https://doi.org/10.1136/bmj.k4723>
- Soliman, E. Z., Backlund, J. Y. C., Bebu, I., Orchard, T. J., Zinman, B., & Lachin, J. M. (2017). Electrocardiographic abnormalities and cardiovascular disease risk in type 1 diabetes: The epidemiology of diabetes interventions and complications (EDIC) study. *Diabetes Care*, *40*(6), 793–799. <https://doi.org/10.2337/dc16-2050>
- Song, Y., Cook, N. R., Albert, C. M., Van Denburgh, M., & Manson, J. E. (2009). Effects of vitamins C and E and β -carotene on the risk of type 2 diabetes in women at high risk of cardiovascular disease: a randomized controlled trial. *The American Journal of Clinical Nutrition*, *90*(2), 429–437. <https://doi.org/https://doi.org/10.3945/ajcn.2009.27491>
- Song, Y., Lobene, A. J., Wang, Y., & Hill Gallant, K. M. (2021). The dash diet and cardiometabolic health and chronic kidney disease: A narrative review of the evidence in east asian countries. In *Nutrients* (Vol. 13, Issue 3, pp. 1–16). MDPI AG. <https://doi.org/10.3390/nu13030984>
- Stanimirovic, J., Radovanovic, J., Banjac, K., Obradovic, M., Essack, M., Zafirovic, S., Gluovic, Z., Gojobori, T., & Isenovic, E. R. (2022). Role of C-Reactive Protein in Diabetic Inflammation. *Mediators of Inflammation*, *2022*, 3706508. <https://doi.org/10.1155/2022/3706508>
- Stern, S., & Sclarowsky, S. (2009). The ecg in diabetes mellitus. In *Circulation* (Vol. 120, Issue 16, pp. 1633–1636). <https://doi.org/10.1161/CIRCULATIONAHA.109.897496>
- Takeda, Y., Matoba, K., Sekiguchi, K., Nagai, Y., Yokota, T., Utsunomiya, K., & Nishimura, R. (2020). Endothelial dysfunction in diabetes. In *Biomedicines* (Vol. 8, Issue 8). MDPI AG. <https://doi.org/10.3390/BIOMEDICINES8070182>
- Taskinen, M.-R. (2003). Diabetic dyslipidaemia: from basic research to clinical practice*. *Diabetologia*, *46*(6), 733–749. <https://doi.org/10.1007/s00125-003-1111-y>

- Teimouri, K., Pakravan, S., & Azadbakht, K. (2022). *The most common electrocardiographic abnormalities in patients with diabetes mellitus Mini-Review*. <https://doi.org/10.34172/jpd.2022.9142>
- Thomakos, P., Liatis, S., Kalopita, S., Vlahodimitris, I., Stathi, C., Katsilambros, N., Tentolouris, N., & Makrilakis, K. (2013). Cigarette smoking is associated with prolongation of the QTc interval duration in patients with type 2 diabetes mellitus. *International Journal of Endocrinology*, 2013. <https://doi.org/10.1155/2013/329189>
- Turner, R., Holman, R., Stratton, I., Cull, C., Frighi, V., Manley, S., Matthews, D., Neil, A., McElroy, H., Kohner, E., Fox, C., Hadden, D., & Wright, D. (1998). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *British Medical Journal*, 317(7160), 703–713. <https://doi.org/10.1136/bmj.317.7160.703>
- Uen, S., Un, I., Fimmers, R., Vetter, H., & Mengden, T. (2006). Myocardial ischemia during everyday life in patients with arterial hypertension: prevalence, risk factors, triggering mechanism and circadian variability. *Blood Pressure Monitoring*, 11(4). https://journals.lww.com/bpmonitoring/Fulltext/2006/08000/Myocardial_ischemia_during_everyday_life_in.1.aspx
- UK Prospective Diabetes Study Group. (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *The Lancet*, 352(9131), 854–865.
- Uloko, E. A., Baba, M. M., Mansur, A. R., Ibrahim, D. G., Fabian, H. P., Ayekame, T. U., Musa, M. B., & Kabiru, B. S. (2018). Prevalence and Risk Factors for Diabetes Mellitus in Nigeria: A Systematic Review and Meta-Analysis. *Diabetes Therapy*, 9(3), 1307–1316. <https://doi.org/10.6084/m9.figshare.6216518>
- Ussher, J. R., & Drucker, D. J. (2023). Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. *Nature Reviews Cardiology*. <https://doi.org/10.1038/s41569-023-00849-3>
- Vasheghani, M., Sarvghadi, F., Beyranvand, M. R., & Emami, H. (2020). The relationship between QT interval indices with cardiac autonomic neuropathy in diabetic patients: a case control study. *Diabetology and Metabolic Syndrome*, 12(1). <https://doi.org/10.1186/s13098-020-00609-0>
- Vasilis, T., Clicerio, G.-V., James, B. M., & Ele, F. (2018). Hypertension and Diabetes mellitus. *Hypertension*, 71(3), 422–428.
- Veglio, M., Borra, M., Stevens, L. K., Fuller, J. H., & Perin, P. C. (1999). *The relation between QTc interval prolongation and diabetic complications. The EURODIAB IDDM Complication Study Group*.
- Veglio, M., Chinaglia, A., & Cavallo, Perin. P. (2000). The clinical utility of QT interval assessment in diabetes. *Diabetes, Nutrition and Metabolism*, 13(6), 356–365.

- Verhoef, P., & Stampfer, M. J. (1995). Prospective Studies of Homocysteine and Cardiovascular Disease. *Nutrition Reviews*, 53(10), 283–288. <https://doi.org/10.1111/j.1753-4887.1995.tb01478.x>
- Vinik, A. I., Maser, R. E., Mitchell, B. D., & Freeman, R. (2003). Diabetic Autonomic Neuropathy. *Diabetes Care*, 26(5), 1553–1579. <https://doi.org/10.2337/diacare.26.5.1553>
- Vinik, A. I., & Ziegler, D. (2007). Diabetic cardiovascular autonomic neuropathy. In *Circulation* (Vol. 115, Issue 3, pp. 387–397). <https://doi.org/10.1161/CIRCULATIONAHA.106.634949>
- Voutilainen, S., Nurmi, T., Mursu, J., & Rissanen, T. H. (2006). Carotenoids and cardiovascular health 2. *The American Journal of Clinical Nutrition*, 83(6), 1265–1271. <https://doi.org/https://doi.org/10.1093/ajcn/83.6.1265>
- Wang, J.-X., You, D.-Y., Wang, H.-P., Zou, C.-G., Yang, Y.-H., Zhang, D., Li, M.-K., Li, C.-M., Lv, J.-Y., Luo, S.-F., Yu, X., Liao, R., & Ma, L.-Q. (2021). Association Between Homocysteine and Type 2 Diabetes Mellitus: a Systematic Review and Meta-analysis. *International Journal of Diabetes in Developing Countries*, 41(4), 553–562. <https://doi.org/10.1007/s13410-021-00933-9>
- Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., Ruff, C. T., Gause-Nilsson, I. A. M., Fredriksson, M., Johansson, P. A., Langkilde, A.-M., & Sabatine, M. S. (2019). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*, 380(4), 347–357. <https://doi.org/10.1056/nejmoa1812389>
- World Health Organization. (2020, April 29). *Healthy Diet*. www.who.int/news-room/fact-sheets/detail/healthy-diet
- Wrexler, Deborah. J. (2022, October 31). *Initial management of hyperglycemia in adults with type 2 diabetes mellitus*. UpToDate. [uptodate.com/contents/initial-management-of-hyperglycemia-in-adults-with-type-2-diabetes-mellitus](https://www.uptodate.com/contents/initial-management-of-hyperglycemia-in-adults-with-type-2-diabetes-mellitus)
- Wright, A. K., Carr, M. J., Kontopantelis, E., Leelarathna, L., Thabit, H., Emsley, R., Buchan, I., Mamas, M. A., van Staa, T. P., Sattar, N., Ashcroft, D. M., & Rutter, M. K. (2022). Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes. *Diabetes Care*, 45(4), 909–918. <https://doi.org/10.2337/dc21-1113>
- Xinyue, H., Tao, B., Zheng, X., Quiju, L., Yang Zheng, & Lu Cai. (2017). Pathophysiological fundamentals of diabetic cardiomyopathy. *Wiley Online Library*, 7(2).
- Yang, X. H., Su, J. Bin, Zhang, X. L., Zhao, L. H., Xu, F., Wang, X. Q., & Cheng, X. B. (2017). The relationship between insulin sensitivity and heart rate-corrected QT interval in patients with type 2 diabetes. *Diabetology and Metabolic Syndrome*, 9(1). <https://doi.org/10.1186/s13098-017-0268-3>

- Yuan, S., Mason, A. M., Carter, P., Burgess, S., & Larsson, S. C. (2021a). Homocysteine, B vitamins, and cardiovascular disease: a Mendelian randomization study. *BMC Medicine*, *19*(1), 97. <https://doi.org/10.1186/s12916-021-01977-8>
- Yuan, S., Mason, A. M., Carter, P., Burgess, S., & Larsson, S. C. (2021b). Homocysteine, B vitamins, and cardiovascular disease: a Mendelian randomization study. *BMC Medicine*, *19*(1), 97. <https://doi.org/10.1186/s12916-021-01977-8>
- Yusuf, S., Dagenais, G., Pogue, J., Bosch, J., & Sleight, P. (2000). *VITAMIN E SUPPLEMENTATION AND CARDIOVASCULAR EVENTS IN HIGH-RISK PATIENTS A BSTRACT*.
- Zhang, P., Zhang, X., Brown, J., Vistisen, D., Sicree, R., Shaw, J., & Nichols, G. (2010). Global healthcare expenditure on diabetes for 2010 and 2030. In *Diabetes Research and Clinical Practice* (Vol. 87, Issue 3, pp. 293–301). <https://doi.org/10.1016/j.diabres.2010.01.026>

UNDER PEER REVIEW